Serum fibronectin 1 and ApoE levels increase with risk of lymphedema in Korean breast cancer survivors

Seung Yun Yim, Eunjung Ryu, Jae Young Lim, Eun Joo Yang, Seung Min Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Lymphedema is an irreversible disorder often seen as a postoperative side effect in breast cancer survivors. We aimed to identify serum factors that are associated with lymphedema risk in breast cancer survivors. Methods: This study recruited 60 volunteer breast cancer survivors. Participants were classified into either a CTRL group who underwent sentinel lymph node biopsy (SLNB), a RISK group who underwent axillary lymph node dissection (ALND) with removal of fewer than five lymph nodes, or an LE group who underwent ALND with removal of more than five lymph nodes. Bioimpedance was measured to determine the ratio of extracellular water (ECW) to total cellular water (TCW) and single-frequency bioimpedance analysis (SFBIA) ratios. Serum lipid profiles were compared among the groups using label-free quantitative proteomics with the nano-liquid chromatography (LC)-tandem mass spectrometer (MS/MS) and emPAI method. Results: The CTRL, RISK, and LE groups had similar body weights and body mass indexes (BMIs) (<25 kg/m2). The LE group showed a higher grade of lymphedema severity compared to the RISK and CTRL groups. Lymphedema indices such as the ECW/TCW ratio and SFBIA ratio at 1 and 5 kHz were greatly increased in the LE group. Serum total cholesterol (total-C) level was higher in the LE group without affecting atherogenic index. Serum proteomics revealed that fibronectin 1 (FN1), apolipoprotein E (ApoE), antithrombin (ANT3), and complement C4 had different abundance values among the groups. ELISA confirmed that FN1 and ApoE were significantly elevated in both the RISK and LE groups compared to the CTRL group. Conclusions: Changes in serum FN1 and ApoE levels were detected prior to changes in serum total-C level and lymphedema indices such as SFBIA ratio. Therefore, elevation in serum FN1 and ApoE concentrations could likely be used to monitor the risk of lymphedema in breast cancer survivors.

Original languageEnglish
Pages (from-to)2319-2326
Number of pages8
JournalSupportive Care in Cancer
Volume23
Issue number8
DOIs
Publication statusPublished - 2015 Aug 29

Fingerprint

Lymphedema
Fibronectins
Survivors
Breast Neoplasms
Serum
Water
Lymph Node Excision
Proteomics
Lymph Nodes
Complement C4
Sentinel Lymph Node Biopsy
Antithrombins
apolipoprotein E1
Hypercholesterolemia
Liquid Chromatography
Volunteers
Body Mass Index
Enzyme-Linked Immunosorbent Assay
Cholesterol
Body Weight

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Yim, Seung Yun ; Ryu, Eunjung ; Lim, Jae Young ; Yang, Eun Joo ; Lee, Seung Min. / Serum fibronectin 1 and ApoE levels increase with risk of lymphedema in Korean breast cancer survivors. In: Supportive Care in Cancer. 2015 ; Vol. 23, No. 8. pp. 2319-2326.
@article{a5ebfd38c62b474b9966c4703e81b430,
title = "Serum fibronectin 1 and ApoE levels increase with risk of lymphedema in Korean breast cancer survivors",
abstract = "Purpose: Lymphedema is an irreversible disorder often seen as a postoperative side effect in breast cancer survivors. We aimed to identify serum factors that are associated with lymphedema risk in breast cancer survivors. Methods: This study recruited 60 volunteer breast cancer survivors. Participants were classified into either a CTRL group who underwent sentinel lymph node biopsy (SLNB), a RISK group who underwent axillary lymph node dissection (ALND) with removal of fewer than five lymph nodes, or an LE group who underwent ALND with removal of more than five lymph nodes. Bioimpedance was measured to determine the ratio of extracellular water (ECW) to total cellular water (TCW) and single-frequency bioimpedance analysis (SFBIA) ratios. Serum lipid profiles were compared among the groups using label-free quantitative proteomics with the nano-liquid chromatography (LC)-tandem mass spectrometer (MS/MS) and emPAI method. Results: The CTRL, RISK, and LE groups had similar body weights and body mass indexes (BMIs) (<25 kg/m2). The LE group showed a higher grade of lymphedema severity compared to the RISK and CTRL groups. Lymphedema indices such as the ECW/TCW ratio and SFBIA ratio at 1 and 5 kHz were greatly increased in the LE group. Serum total cholesterol (total-C) level was higher in the LE group without affecting atherogenic index. Serum proteomics revealed that fibronectin 1 (FN1), apolipoprotein E (ApoE), antithrombin (ANT3), and complement C4 had different abundance values among the groups. ELISA confirmed that FN1 and ApoE were significantly elevated in both the RISK and LE groups compared to the CTRL group. Conclusions: Changes in serum FN1 and ApoE levels were detected prior to changes in serum total-C level and lymphedema indices such as SFBIA ratio. Therefore, elevation in serum FN1 and ApoE concentrations could likely be used to monitor the risk of lymphedema in breast cancer survivors.",
author = "Yim, {Seung Yun} and Eunjung Ryu and Lim, {Jae Young} and Yang, {Eun Joo} and Lee, {Seung Min}",
year = "2015",
month = "8",
day = "29",
doi = "10.1007/s00520-014-2588-2",
language = "English",
volume = "23",
pages = "2319--2326",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "8",

}

Serum fibronectin 1 and ApoE levels increase with risk of lymphedema in Korean breast cancer survivors. / Yim, Seung Yun; Ryu, Eunjung; Lim, Jae Young; Yang, Eun Joo; Lee, Seung Min.

In: Supportive Care in Cancer, Vol. 23, No. 8, 29.08.2015, p. 2319-2326.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum fibronectin 1 and ApoE levels increase with risk of lymphedema in Korean breast cancer survivors

AU - Yim, Seung Yun

AU - Ryu, Eunjung

AU - Lim, Jae Young

AU - Yang, Eun Joo

AU - Lee, Seung Min

PY - 2015/8/29

Y1 - 2015/8/29

N2 - Purpose: Lymphedema is an irreversible disorder often seen as a postoperative side effect in breast cancer survivors. We aimed to identify serum factors that are associated with lymphedema risk in breast cancer survivors. Methods: This study recruited 60 volunteer breast cancer survivors. Participants were classified into either a CTRL group who underwent sentinel lymph node biopsy (SLNB), a RISK group who underwent axillary lymph node dissection (ALND) with removal of fewer than five lymph nodes, or an LE group who underwent ALND with removal of more than five lymph nodes. Bioimpedance was measured to determine the ratio of extracellular water (ECW) to total cellular water (TCW) and single-frequency bioimpedance analysis (SFBIA) ratios. Serum lipid profiles were compared among the groups using label-free quantitative proteomics with the nano-liquid chromatography (LC)-tandem mass spectrometer (MS/MS) and emPAI method. Results: The CTRL, RISK, and LE groups had similar body weights and body mass indexes (BMIs) (<25 kg/m2). The LE group showed a higher grade of lymphedema severity compared to the RISK and CTRL groups. Lymphedema indices such as the ECW/TCW ratio and SFBIA ratio at 1 and 5 kHz were greatly increased in the LE group. Serum total cholesterol (total-C) level was higher in the LE group without affecting atherogenic index. Serum proteomics revealed that fibronectin 1 (FN1), apolipoprotein E (ApoE), antithrombin (ANT3), and complement C4 had different abundance values among the groups. ELISA confirmed that FN1 and ApoE were significantly elevated in both the RISK and LE groups compared to the CTRL group. Conclusions: Changes in serum FN1 and ApoE levels were detected prior to changes in serum total-C level and lymphedema indices such as SFBIA ratio. Therefore, elevation in serum FN1 and ApoE concentrations could likely be used to monitor the risk of lymphedema in breast cancer survivors.

AB - Purpose: Lymphedema is an irreversible disorder often seen as a postoperative side effect in breast cancer survivors. We aimed to identify serum factors that are associated with lymphedema risk in breast cancer survivors. Methods: This study recruited 60 volunteer breast cancer survivors. Participants were classified into either a CTRL group who underwent sentinel lymph node biopsy (SLNB), a RISK group who underwent axillary lymph node dissection (ALND) with removal of fewer than five lymph nodes, or an LE group who underwent ALND with removal of more than five lymph nodes. Bioimpedance was measured to determine the ratio of extracellular water (ECW) to total cellular water (TCW) and single-frequency bioimpedance analysis (SFBIA) ratios. Serum lipid profiles were compared among the groups using label-free quantitative proteomics with the nano-liquid chromatography (LC)-tandem mass spectrometer (MS/MS) and emPAI method. Results: The CTRL, RISK, and LE groups had similar body weights and body mass indexes (BMIs) (<25 kg/m2). The LE group showed a higher grade of lymphedema severity compared to the RISK and CTRL groups. Lymphedema indices such as the ECW/TCW ratio and SFBIA ratio at 1 and 5 kHz were greatly increased in the LE group. Serum total cholesterol (total-C) level was higher in the LE group without affecting atherogenic index. Serum proteomics revealed that fibronectin 1 (FN1), apolipoprotein E (ApoE), antithrombin (ANT3), and complement C4 had different abundance values among the groups. ELISA confirmed that FN1 and ApoE were significantly elevated in both the RISK and LE groups compared to the CTRL group. Conclusions: Changes in serum FN1 and ApoE levels were detected prior to changes in serum total-C level and lymphedema indices such as SFBIA ratio. Therefore, elevation in serum FN1 and ApoE concentrations could likely be used to monitor the risk of lymphedema in breast cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=84932635157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932635157&partnerID=8YFLogxK

U2 - 10.1007/s00520-014-2588-2

DO - 10.1007/s00520-014-2588-2

M3 - Article

C2 - 25577503

AN - SCOPUS:84932635157

VL - 23

SP - 2319

EP - 2326

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 8

ER -